Your browser doesn't support javascript.
Therapeutic targeting of interleukin-6 for the treatment of COVID-19.
Wang, Yao; Liu, Chen; Miao, Xiaolong; Kong, Deqiang; Zhao, Yingli; Gong, Weihua; Ding, Xianfeng.
  • Wang Y; College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, Zhejiang, China.
  • Liu C; Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou 310058, China.
  • Miao X; Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou 310058, China.
  • Kong D; Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou 310058, China.
  • Zhao Y; Department of Infectious Diseases, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou 310058, China.
  • Gong W; Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou 310058, China.
  • Ding X; College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, Zhejiang, China.
Eur Cytokine Netw ; 2020 Dec 03.
Article in English | MEDLINE | ID: covidwho-955345
Semantic information from SemMedBD (by NLM)
1. cytokine ASSOCIATED_WITH COVID-19
Subject
cytokine
Predicate
ASSOCIATED_WITH
Object
COVID-19
2. Cytokine Release Syndrome CAUSES COVID-19
Subject
Cytokine Release Syndrome
Predicate
CAUSES
Object
COVID-19
3. interleukin-6 AFFECTS Immune
Subject
interleukin-6
Predicate
AFFECTS
Object
Immune
4. sarilumab TREATS Cytokine Release Syndrome
Subject
sarilumab
Predicate
TREATS
Object
Cytokine Release Syndrome
5. cytokine ASSOCIATED_WITH COVID-19
Subject
cytokine
Predicate
ASSOCIATED_WITH
Object
COVID-19
6. Cytokine Release Syndrome CAUSES COVID-19
Subject
Cytokine Release Syndrome
Predicate
CAUSES
Object
COVID-19
7. interleukin-6 AFFECTS Immune
Subject
interleukin-6
Predicate
AFFECTS
Object
Immune
8. sarilumab TREATS Cytokine Release Syndrome
Subject
sarilumab
Predicate
TREATS
Object
Cytokine Release Syndrome
ABSTRACT
Coronavirus disease 19 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in China and has spread worldwide with a significant rate of infection. Considering the elevated levels of proinflammatory cytokines in COVID-19, it is suggested that cytokine storms play a critical role in its pathogenesis, including acute respiratory distress syndrome (ARDS). However, there is no specific drug for preventing the cytokine release syndrome (CRS) caused by COVID-19. Indeed, interleukin 6 (IL-6) has been highlighted for its many biological functions, such as immune regulation, inflammatory response, and metabolism. Therapeutic blockade of the IL-6 signaling pathway is expected to reduce the excessive immune reponse observed in COVID-19. Currently, the IL-6 receptor antagonists tocilizumab and sarilumab, have been adopted for preventing CRS during the progression of COVID-19, and remarkable beneficial effects were observed by using these humanized monoclonal antibodies. Based on the pathogenesis of COVID-19, we reviewed the biological mechanism of IL-6 blockade in the treatment of SARS-CoV-2 infection and evaluated its clinical applications.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal subject: Allergy and Immunology Year: 2020 Document Type: Article Affiliation country: Ecn.2020.0453

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal subject: Allergy and Immunology Year: 2020 Document Type: Article Affiliation country: Ecn.2020.0453